Subgroup analysis found that from the US healthcare sector perspective, the cost-effectiveness models basing on the median cycle number of drugs delivered in the CAPSTONE-1 were sensitive to age, sex, ECOG performance status, smoking history, LDH concentration at enrolment, status of liver metastases, and PD-L1 tumor proportion score. The gene discussed is CD274; the disease is neoplasm.